Response by Barreto and Grotta to Letter Regarding Article, “Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Dr Shah for his interest and insightful comments on our randomized trial of adjunctive argatroban administered to recombinant tissue plasminogen activator (r-tPA)–treated patients with stroke (ARTSS-2 [Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke]).1 Compared with r-tPA alone, ARTSS-2 demonstrated safety and improved clinical outcomes in patients who received combination r-tPA and argatroban. In general, we are in complete agreement with Dr Shah’s comments and would like to make the following points.
Dr Shah correctly points out our hypothesis that adjunctive argatroban enhances recanalization of proximal, large vessel occlusions. Although our current study did not show …